Zimmerman Amanda, Laitman Adam
West Forsyth Pain Management, Winston Salem, NC 27103, USA.
Salix Pharmaceuticals, Bridgewater, NJ 08807, USA.
J Clin Med. 2024 May 7;13(10):2746. doi: 10.3390/jcm13102746.
In the palliative care population, prescription opioids are often considered viable pain relief options. However, in this complex patient population, the adverse effects of opioid medications should be identified and managed without delay. Common adverse effects can include constipation, nausea, somnolence, dizziness, vomiting, and pruritus. Less common adverse effects can include potentially lethal respiratory depression and cardiovascular effects. Critical aspects of safe opioid prescribing are recognition of side effects and knowledge of effective management strategies; prompt management is necessary for uninterrupted pain relief. Most complications are managed with general approaches such as dose reduction, opioid rotation, alternate routes of administration, and symptomatic management. The only opioid-induced complication for which US Food and Drug Administration-approved treatments currently exist is constipation. Treating laxative-refractory opioid-induced constipation (OIC) with peripherally acting mu-opioid receptor antagonists (PAMORAs), which block gastrointestinal opioid receptors, can restore gastrointestinal motility and fluid secretion. This narrative review discusses key complications of prescription opioid treatment and their management in the palliative care setting.
在姑息治疗人群中,处方阿片类药物通常被认为是可行的疼痛缓解选择。然而,在这个复杂的患者群体中,阿片类药物的不良反应应立即被识别并加以处理。常见的不良反应可能包括便秘、恶心、嗜睡、头晕、呕吐和瘙痒。较不常见的不良反应可能包括潜在致命的呼吸抑制和心血管效应。安全开具阿片类药物的关键在于识别副作用和了解有效的管理策略;及时处理对于持续缓解疼痛是必要的。大多数并发症通过一般方法进行处理,如减少剂量、更换阿片类药物、采用替代给药途径和对症处理。目前美国食品药品监督管理局批准的治疗方法仅针对阿片类药物引起的便秘这一并发症。使用外周作用的μ-阿片受体拮抗剂(PAMORAs)治疗对泻药难治的阿片类药物引起的便秘(OIC),这类药物可阻断胃肠道阿片受体,能够恢复胃肠蠕动和液体分泌。这篇叙述性综述讨论了处方阿片类药物治疗的关键并发症及其在姑息治疗环境中的管理。